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Cell signaling plays an important role in directing the pheno-
typic changes that mesangial cells undergo in glomerular dis-
ease. These changes include increased synthesis and reorgani-
zation of extracellular matrix, protease secretion, processing of
extracellular macromolecules such as immune complexes, and
cell growth in the form of hypertrophy and hyperplasia [1].
Although rearrangements or mutations in the mesangial genome
might account for some of these phenotypic alterations, it is
now clear that many of these changes result from regulation of
gene expression by extracellular ligands. Proinflammatory li-
gands, such as growth factors, cytokines, and peptides, evoke a
network of short-term signals that are extended to long-term
events involving differential regulation of gene expression. But
despite recent advances, the pathways of signaling by which
these ligands regulate the genetic program of mesangial cells
remain unclear.
To understand how extracellular stimuli regulate mesangial
phenotype, we have focused on the recently described peptide
hormones, endothelins (ET) [2]. ET are a widely expressed
family of 21-amino acid peptides with diverse biological actions
[reviewed in 2, 3]. ET peptides are expressed at numerous sites
in the kidney, but glomerular ET is thought to arise mostly from
the glomerular endothelium [4] and from mesangial cells them-
selves [5, 61. Secreted ET binds to receptors on the mesangial
cell plasma membrane and initiates a cascade of signals that
cause both short-term and long-term actions [7]. Short-term
actions are directed primarily at the regulation of mesangial cell
contraction [8—111 and secretion [8]. But the fact that ET is a
potent mitogen in mesangial cells [121 reveals that ET also
stimulates differential gene expression. ET has already been
shown to increase expression of genes for the c-fos protoonco-
gene [12] and for the platelet-derived growth factor A and B
chains [13]. Thus, cultured mesangial cells provide a valuable
model to study the pathway of signaling from cytosol to nucleus
and the possible implications for glomerular disease.
The pathways of ET signaling are becoming clear, although
obvious gaps in our understanding remain. Figure 1 summarizes
a working model of the signal transduction pathways activated
by ET in mesangial cells. We first briefly describe the cytosolic
second messengers generated by interaction of ET with plasma
membrane receptors. Finally, we will explain how these cyto-
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solic signals regulate the AP-1 family of inducible trans-activa-
tors, thereby controlling the genetic program of mesangial cells.
Receptors for ET and short-term signals
The pathway of signal transduction in mesangial cells is
initiated by binding of ET ligands to integral membrane recep-
tors of two different subtypes [14—161. These receptors can be
classified experimentally on the basis of differential affinity for
ET ligands [14, 15] and by cross linking and electrophoretic
separation [16]. ET receptors belong to the G protein-coupled
receptor family and share many features with other well-
characterized members of this family such as the rhodopsin,
adrenergic, and muscarinic receptors [17, 181. ET receptors,
like other G protein-coupled receptors, couple to numerous
effector systems via the action of G proteins [19]. To date, ET
receptors have not been cloned in mesangial cells, and cloning
of receptor subtypes will enable studies aimed at structure!
function relationships, regulation of expression, the role of ET
receptors in desensitization, and perhaps the rational design of
specific receptor blockers.
At least two mechanisms account for the diversity of cyto-
solic signals emanating from ET receptors (Fig. 1) (see [3] for a
thorough discussion of ET signaling). Different receptor sub-
types appear to activate distinct signaling systems. In addition,
single G protein-coupled receptors interact with multiple G
proteins, which can in turn regulate different effectors. In
mesangial cells the lower-affinity ET receptor couples directly
to many signaling systems including phospholipases C, D and
A2, and directly or indirectly to Ca2 channels and Na!H
antiporters [8—12]. These signals mediate both the contraction
of mesangial cells and secretion of bioactive prostaglandins [8].
In contrast, the high-affinity receptor appears to open a ligand-
gated Ca2 channel, but the mechanism and biological signifi-
cance of this response remains unclear. However, this high-
affinity receptor subtype might mediate a hypertrophic response
in mesangial cells (Simonson and Dunn, unpublished observa-
tions).
Nuclear signaling by ET peptides
We next turn to the question of how the short-term signals
discussed above are extended to regulate gene expression in the
nucleus. To regulate the expression of target genes, ET must
somehow alter the activity of transcriptional proteins involved
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in the RNA polymerase II complex, coactivators, or trans-
acting factors. Current evidence suggests that gene expression
in response to environmental signals occurs by regulating the
activity of inducible trans-acting factors. AP-l (activator pro-
tein- 1) complexes are prototypes for factors that couple recep-
tor-generated second messengers to long-term responses re-
quiring differential gene regulation [reviewed in 20—22].
Fig. 1. Pathway of signal transduction from membrane to nucleus
following activation of ET receptors. ET ligands bind to G protein-
coupled receptors in the plasma membrane. Activated ET receptors
interact with heterotrimeric G proteins and promote both the exchange
of GTP for GDP and the dissociation of GTP-bound alpha subunit. A
complicated network of effectors is then activated by the free alpha
subunit, resulting in production of multiple second messengers includ-
ing inositol (1 ,4,5)P3, diacylglycerol, prostaglandins, phosphatidic acid,
etc. These second messengers may activate as yet unidentified protein
kinases that extend these cytosolic signals to the nucleus. These signals
ultimately result in activation of upstream regulatory elements (URE) in
AP- I genes to stimulate transcription and the production of various
AP-l dimers. The dotted line indicates that AP-l complexes can also be
regulated post-translationally. The net effect of AP-l induction is to
direct the transcription of target genes (that is, delayed genes) and alter
the genetic program of mesangial cells.
Induction of AP- I factors contributes to diverse phenotypic
responses including cell growth and differentiation. In short,
AP- I complexes function as a switch to coordinate the genetic
program of cells with changing extracellular signals.
AP-l consists of a mixture of homodimers and heterodimers
that bind to cis-acting elements (TGACTCA or close variants
thereof) in upstream promotor or enhancer regions of genes.
Interactions of bound AP-l with unidentified components of the
basal transcriptional apparatus regulate the initiation rate of
RNA polymerase II. AP-l complexes are encoded by two
families of closely related genes: (i) the fbs family including
c-fos, fos B, and fra-l [23]; and (ii) the jun family including
c-fun, jun B, and jun D [21]. Fos and fun monomers then
dimerize to form functional homo- or heterodimer AP- 1 com-
plexes, and dimerization is required for sequence-specific DNA
binding. Dimerization of fos and jun proteins occurs through a
leucine zipper motif that consists of a periodic repetition of
leucine residues at every seventh position [24]. Thus, the
composition of AP- 1 isolated from nuclear extracts consists of
variable dimer complexes [22, 25, 26]. These dimers not only
have different affinities for the AP-l binding site but are also
thought to have different trans-activating potential.
There is abundant evidence that the magnitude and pattern of
AP-l gene expression regulates AP-1 activity. Induction of
AP- 1 genes not only controls the concentration of these factors
but also regulates in part the relative composition of AP- 1
dimers. The composition of AP- 1 dimers has important conse-
quences for AP-1 action. For example, different dimers have
variable affinities for AP-1 cis-acting elements, with fos:jun
heterodimers having greater affinity that jun jun homodimers
[21, 27]. Moreover, qualitative and quantitative differences in
DNase-1-hypersensitivity sites between different AP-l dimers
suggest that these proteins differ in size and shape [22]. It is also
possible that distinct AP-1 dimers have different affinities for
groups of closely related AP-1 sites in the promoters of target
genes. In addition, distinct AP-l dimers might bind to similar
elements in separate genes but have different trans-activational
effects on the basal transcriptional machinery [22, 28]. For
example, c-fos:c-jun dimers activate transcription whereas
c-fos:jun B complexes appear, under some conditions, to re-
press transcription [28]. Thus, regulation of gene expression for
AP-l complexes is an important determinant of AP-l activity.
To investigate whether AP-l might mediate some of the
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catalyzed by a protein phosphatase [30]. By contrast, Ha-Ras
amplifies trans-activation by c-jun via phosphorylation of its
activation domain [311. AP-1 proteins also bear multiple
0-linked N-acetylglucosamine monosaccharide residues [321,
although the functional significance of glycosylation is not
clear, At present it is unknown whether ET regulates AP-l
2.2 kb through post-translational modifications.
Regulation of the mesangial cell genetic program by AP-1
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Fig. 2. ET-l and ET-3 evoke differential induction of mRNA abun-
dance for AP-1 genes. Quiescent rat mesangial cells were treated at
zero time with 0.1 uM ET-3 or ET-!. At the times indicated, total RNA
was extracted, fractionated in agarose gels, and transferred to nitrocel-
lulose. The steady-state mRNA levels were then analyzed by Northern
RNA blot analysis using [32P]-labeled cDNA probes for specific AP-1
genes. The same blot was rehybridized with a eDNA probe for
glyceraldehyde phosphate dehydrogenase (GAPDH) to control for
differences in RNA loading and for global changes in RNA polymerase
II activity.
nuclear events stimulated by ET, we asked if ET differentially
regulates AP-1 gene induction in mesangial cells. ET isopep-
tides, ET-1 and ET-3, markedly stimulate the steady-state
mRNA levels for several AP-l genes including c.fos,fra-l, and
c-jun (Note added in proof; Fig. 2). Several points regarding the
AP-l response are noteworthy. Induction of AP-l expression
occurs rapidly after the addition of ET and is consistent with a
role in cell signaling. The expression of some AP-1 genes such
as c-jun and fra- I are sustained while genes such as c-fos are
only transiently induced. The rapid reversal of c-fos mRNA
abundance is likely due to negative autoregulation of c-fos
transcription by AP-1 complexes [29], which is thought to limit
the accumulation of fos in response to incoming signals. In
addition, ET-1 and ET-3 differentially regulate AP-1 induction,
which might help explain the different biological effects of these
peptides (Note added in proof). ET-l stimulates all three AP-1
genes, whereas ET-3 fails to stimulate c-fos induction and
stimulates c-jun and fra-1 to a lesser extent than ET-l. Taken
together, these experiments suggest that AP-1 complexes con-
tribute to the control of gene expression by ET peptides.
Experiments are now underway to investigate the mechanisms
by which ET regulates trans-activation by AP-l.
Do other ET-stimulated pathways regulate AP- I activity?
AP-l activity is controlled at the transcriptional, post-transcrip-
tional, and post-translational levels [211, and it is possible that
ET acts at all levels. AP-l are phosphoproteins, and reversible
phosphorylation/dephosphorylation plays an important role in
regulating AP-1 activity. For example, in response to protein
kinase C c-jun is activated by site-specific dephosphorylation
1.8 What are the biological consequences of AP-l induction by
ET? AP-1 genes belong to the immediate-early response genes,
which regulate the network of genes responsible for long-term
changes such as proteases, receptors, ion channels, cytoskele-
2.8 tal proteins, and other trans-acting factors. At present, little is
known about the biological consequences of AP- 1 induction in
mesangial cells. The best evidence in support of AP- 1 action in
mesangial cells is induction of the collagenase gene by ET (Note
1.4 added in proof). The collagenase promoter contains an AP-l
cis-acting element and is a well-characterized target for tran-
scriptional regulation by AP- 1. Because protease secretion
contributes to the development of glomerular inflammation, it is
tempting to speculate that in glomerulonephritis AP- 1 elements
mediate increased protease secretion. In addition, AP-1 factors
have been implicated in various aspects of cell growth including
mitogenesis, differentiation, and development [25]. Our prelim-
inary studies suggest that induction of fos proteins correlates
with a hypertrophic response in mesangial cells whereas induc-
tion of jun proteins correlates with a hyperplastic response.
Clearly, the identification of late response genes in mesangial
cells that are direct targets for AP-l factors is of pressing
importance. These experiments should be facilitated by the
identification of AP- 1 elements in the promoters or enhancers of
target genes and by a detailed analysis of AP- 1 activity in
mesangial cells.
Concluding remarks
Despite much progress, many questions regarding the path-
way of signal transduction from membrane receptor to the
nucleus remain: 1) What is the nature of ET receptor genes in
mesangial cells and how is their expression regulated? 2) What
intermediary protein kinases (that is, Raf, MAP, S6, etc.)
contribute to the transcriptional and post-translational regula-
tion of AP-1 in response to ET? 3) What are the target genes
responsive to AP-l factors? 4) What other inducible trans-
acting factors play a role in nuclear signaling by ET? 5) How is
the AP- 1 signaling pathway turned off, and can we develop
pharmacological tools to interdict these pathways? Future
efforts aimed at analyzing the regulation of AP- 1 and other
inducible trans-acting factors is likely to provide significant
insight into the mechanisms controlling mesangial phenotype in
glomerular inflammation.
Note added in proof
SIM0N50N MS, JONES JM, DUNN MJ: Differential regulation of fos
and jun gene expression and AP-l cis-element activity by endothelin
isopeptides: Possible implications for mitogenic signaling by endothe-
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Simonson et al: Endothelin peptides 545
Acknowledgments
This work was supported by National Institutes of Health Grant
HL-22563 and DK-41684.
Reprint requests to Michael J. Dunn, M.D., Department of Medi-
cine, University Hospitals, 2074 Abington Road, Cleveland, Ohio
44106, USA.
References
1. STERZEL RB, LOVETT DH: Interactions of inflammatory and gb-
merular cells in the response to glomerular injury, in Contemporary
Issues in Nephrology (vol 18), edited by BRENNER BM, STEIN JH
New York, Churchill Livingstone, 1988, p. 137
2, YANAGISAWA M, KURIHARA H, KIMURA S, TOMBE Y, KOBAYASHI
M, MITSUI Y, YAZAKI Y, GoTo K, MASAKI T: A novel potent
vasoconstrictor peptide produced by vascular endothelial cells.
Nature 332:411—415, 1988
3. SIMONSON MS, DUNN Mi: Cellular signaling by peptides of the
endothelin gene family. FASEB J 4:2989—3000, 1990
4. MARSDEN PA, DORFMAN DM, COLLINS T, BRENNER BM, ORKIN S,
BALLERMANN BJ: Regulated expression of endothelin-1 in glomer-
ular capillary endothelial cells. Am J Physiol 261:Fl17—F125, 1991
5. SAKAMOTO H, SASAKI S, HIRATA Y, IMAI T, ANDO K, IDA T,
SAKURAI 1, YANAGISAWA M, MASAKI T, MARIJMO F: Production
of endothelin-l by rat cultured mesangial cells. Biochem Biophys
Res Comm 169:462—468, 1990
6. ZOJA C, ORIslo S, PERICO N, BENIGNI A, M0RIGI M, BENATTI L,
RAMBALDI A, REMUZZI G: Constitutive expression of endothelin
gene in cultured human mesangial cells and its modulation by
transforming growth factor b, thrombin, and a thromboxane A2
analogue. Lab Invest 64:16—25, 1991
7. SIMONSON MS, DUNN Mi: Endothelin: Pathways of transmem-
brane signaling. Hypertension l5(Sl):15—112, 1990
8. SIMONSON MS, DUNN Mi: Endothelin-1 stimulates contraction of
rat glomerular mesangial cells and potentiates 3-adrenergic-medi-
ated cyclic adenosine monophosphate accumulation. J Clin Invest
85:790—797, 1990
9. SIMONSON MS, DUNN Mi: Ca2 signaling by distinct endothelin
peptides in glomerular mesangial cells. Exp Cell Res 192:148—156,
1991
10. SIM0Ns0N MS, OSANAI T, DUNN MJ: Endothelin isopeptides
evoke Ca2 signaling and oscillations of cytosolic free [Ca2] in
human mesangial cells. Biochim Biophys Acta 1055:63—68, 1990
11. BADR KF, MURRAY ii, BREYER MD, TAKAHASHI K, INAGAMI T,
HARRIS RC: Mesangial cell, glomerular, and renal vascular re-
sponses to endothelin in the kidney. J Clin Invest 83:336—342, 1989
12. SIM0Ns0N MS, WANN S, MENE' P, DUBYAK G, KESTER M,
NAKAZATO Y, SEDOR JR, DUNN Mi: Endothelin stimulates phos-
pholipase C, Na/H exchange, c-fos expression, and mitogenesis
in rat mesangial cells. J Clin Invest 83:708—712, 1989
13. JAFFER FE, KNAUSS TC, POPTIC E, ABBOUD HE: Endothelin
stimulates PDGF secretion in cultured human mesangial cells.
Kidney mt 38:1193—1198, 1990
14. BADR KF, MUNGER KA, SUGIURA M, SNAJDAR RM, SCHWARTZ-
BERG M, INAGAMI T: High and low affinity binding sites for
endothelin on cultured rat glomerular mesangial cells. Biochem
Biophys Res Comm 161:776—781, 1989
15. BALDI E, DUNN MJ: Endothelin binding and receptor down-
regulation in rat glomerular mesangial cells. J Pharmacol Exp Ther
256:581—586, 1991
16. MARTIN ER, BRENNER BM, BALLERMANN BJ: Heterogeneity of
cell surface endothelin receptors. J Biol Chem 265:14044—14049,
1990
17. ARAI H, H0RI S, ARAMORI 1, OHKUBO H, NAKANISHI S: Cloning
and expression of a cDNA encoding an endothelin receptor. Nature
348:730—732, 1990
18. SAKURAI T, YANAGISAWA M, TAKUWA Y, MIYAzAIu H, KIMURA
S, GOTO K, MASAKI T: Cloning of a cDNA encoding a non-
isopeptide-selective subtype of the endothelin receptor. Nature
348:732—735, 1990
19. THOMAS CP, KESTER M, DUNN Mi: A pertussis toxin sensitive
GTP-binding protein couples endothelin to phospholipase C in rat
mesangial cells. Am J Physiol 260:F347—F352, 1991
20. KARIN M: The AP-1 complex and its role in transcriptional control
by protein kinase C, in Molecular Aspects of Cellular Regulation
(vol 6), edited by COHEN P, FOULKES G, Amsterdam, Elsevier/
North Holland, 1990, p. 143
21. VOGT PK, Bos Ti: fun: Oncogene and transcription factor. Adv
Cancer Res 55: 1—35, 1991
22. BOHMANN D, ADMON A, TURNER DR, TJIAN R: Transcriptional
regulation by the AP-1 family of enhancer-binding proteins: A
nuclear target for signal transduction. Cold Spring Harbor Symp
Quant Biol 53:695—700, 1988
23. CURRAN 1: Thefos oncogene, in The Oncogene Handbook, edited
by REDDY EP, SKALKA AM, CURRAN T, Amsterdam, Elsevier,
1988, p. 307
24. LANDSCHULTZ WH, JOHNSON PF, MCKNIGHT SL: The leucine
zipper: A hypothetical structure common to a new class of DNA
binding proteins. Science 240:1759—1764, 1988
25. CURRAN T, FRANZA BR: Fos and fun: The Ap-l connection. Cell
55:395—397, 1988
26. COHEN DR, FERREIRA P, GENTZ R, FRANZA BR, CURRAN T: The
product of afos-related gene, fra-l, binds cooperatively to the AP-l
site with fun: Transcription factor AP-1 is comprised of multiple
protein complexes. Gene Dev 3:173—184, 1989
27. KOUZARIDES T, ZIFF E: Behind the Fos and Jun leucine zipper.
Cancer Cell 1:71—76, 1989
28. CHIU R, ANGEL P, KARIN M: Jun-B differs in its biological
properties from, and is a negative regulator of, c-jun. Cell 59:979—
986, 1989
29. SA5S0NE-COR5I P, SissoN JC, VERMA IM: Transcriptional autoreg-
ulation of the protooncogene fos. Nature 334:314—319, 1988
30. BOYLE WJ, SMEAL T, DEFIZE LHK, ANGEL P, WOODGETT JR.
KARIN M, HUNTER T: Activation of protein kinase C decreases
phosphorylation of c-jun at sites that negatively regulate its DNA-
binding activity. Cell 64:573—584, 1991
31. BINETRUY B, SMEAL T, KARIN M: Ha-Ras augments c-jun activity
and stimulates phosphorylation of its activation domain. Nature
351:122—127, 1991
32. JACKSON SP, TJIAN R: 0-glycosylation of eukaryotic transcription
factors: Implications for mechanisms of transcriptional regulation.
Cell 55:125—133, 1988
